Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 8 of 8 entries
View as:

Safety and Efficacy of ALLO-316 in Subjects With Advanced or Metastatic Clear Cell Renal Cell Carcinoma

Phase: N/A Priority: Normal
NCT ID: NCT04696731 Org: User:
Start: 02/24/21 End: 10/31/25 Due: 10/31/26

Safety and Efficacy of ALLO-501 Anti-CD19 Allogeneic CAR T Cells in Adults With Relapsed/Refractory Large B Cell or Follicular Lymphoma

Phase: N/A Priority: Normal
NCT ID: NCT03939026 Org: User:
Start: 05/01/19 End: 08/31/26 Due: 08/31/27

Safety and Efficacy of ALLO-715 BCMA Allogenic CAR T Cells in in Adults With Relapsed or Refractory Multiple Myeloma (UNIVERSAL)

Phase: N/A Priority: Normal
NCT ID: NCT04093596 Org: User:
Start: 09/23/19 End: 09/30/27 Due: 09/30/28

Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL

Phase: N/A Priority: Normal
NCT ID: NCT06500273 Org: User:
Start: 06/18/24 End: 08/24/31 Due: 08/24/32

Follow-Up for Study Participants Treated With an Allogeneic CAR T-Cell Product

Phase: N/A Priority: Normal
NCT ID: NCT06925685 Org: User:
Start: 01/31/25 End: 01/31/39 Due: 01/31/40

Evaluation of Lymphodepletion With ALLO-647 in Adults With R/R Large B Cell Lymphoma Receiving ALLO-501A Allogeneic CAR T Cell Therapy

Phase: N/A Priority: Normal
NCT ID: NCT05714345 Org: User:
Start: 03/31/23 End: 10/31/29 Due: 10/31/30

Safety and Efficacy of ALLO-605 an Anti-BCMA Allogeneic CAR T Cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma

Phase: N/A Priority: Normal
NCT ID: NCT05000450 Org: User:
Start: 06/06/21 End: 10/11/23 Due: 10/11/24

Safety and Efficacy of ALLO-501A Anti-CD19 Allogeneic CAR T Cells in Adults with Relapsed/Refractory Large B Cell Lymphoma, Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma (ALPHA2)

Phase: N/A Priority: Normal
NCT ID: NCT04416984 Org: User:
Start: 05/21/20 End: 05/31/29 Due: 05/31/30